KALY management wants to stay involved in the ongoing biopharmaceutical developments even after a possible sale.
DALLAS, Oct. 31, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced taking a next step with the investor that has recently valued KALY’s biopharmaceutical technology at $50 Million.
The valuation has been presented to KALY by an investor interested in acquiring KALY’s U.S. Patented Cannabis Extraction Process and associated biopharmaceutical research and developments.
KALY management has asked the investor to provide a “working” term-sheet for discussion purposes.
The proposed transaction has KALY maintaining rights to its Patented Cannabis Extraction Process for business pursuits other than pharmaceutical developments such as the cannabis infused beverage and candy business it currently conducts.
KALY would also continue its CBD extraction business provided to hemp cultivation operations.
KALY management considers the valuation consistent with Goldman Small Cap Research’s recent valuation, but management maintains a position that the valuation still does not reflect the full potential of its intellectual property.
KALY management wants to stay involved in the ongoing biopharmaceutical developments even after a possible sale.
